MARKET

CYCC

CYCC

Cyclacel Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.79
+0.23
+3.51%
Closed 16:00 05/14 EDT
OPEN
6.59
PREV CLOSE
6.56
HIGH
6.85
LOW
6.48
VOLUME
138.20K
TURNOVER
--
52 WEEK HIGH
11.42
52 WEEK LOW
3.120
MARKET CAP
62.70M
P/E (TTM)
-1.5606
1D
5D
1M
3M
1Y
5Y
BRIEF-Cyclacel Pharmaceuticals Reports First Quarter 2021 Financial Results
reuters.com · 2d ago
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers
Benzinga · 2d ago
Cyclacel Pharmaceuticals EPS misses by $0.99
Cyclacel Pharmaceuticals (CYCC): Q1 GAAP EPS of -$1.48 misses by $0.99.As of March 31, 2021, cash and cash equivalents totaled $47.8 million, compared to $33.4 million as of December 31,
Seekingalpha · 2d ago
Cyclacel Pharmaceuticals, Inc. to Host Earnings Call
ACCESSWIRE · 2d ago
The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 11)
Benzinga · 2d ago
Earnings Scheduled For May 12, 2021
  Companies Reporting Before The Bell • PolyPid (NASDAQ:PYPD) is estimated to report earnings for its first quarter.
Benzinga · 2d ago
Bionano (BNGO) to Report Q1 Earnings: What's in the Cards?
Zacks.com · 4d ago
Pituitary ACTH Hypersecretion Drug Market 2021 Analysis, Industry Size, Share Leaders, Current Status By Major vendors and Trends By Forecast to 2028 By Ameco Research
pune, India, Fri, 07 May 2021 03:18:44 / Comserve Inc. / -- The global Pituitary ACTH Hypersecretion Drug market is segmented by company, region (country),...
Comserve · 05/07 07:20
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CYCC. Analyze the recent business situations of Cyclacel Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CYCC stock price target is 20.25 with a high estimate of 24.00 and a low estimate of 17.00.
EPS
Institutional Holdings
Institutions: 25
Institutional Holdings: 1.67M
% Owned: 18.13%
Shares Outstanding: 9.23M
TypeInstitutionsShares
Increased
1
11.25K
New
11
1.58M
Decreased
1
2.99K
Sold Out
3
154.65K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.85%
Pharmaceuticals & Medical Research
+1.12%
Key Executives
Chairman/Director
David U'Prichard
President/Chief Executive Officer/Director
Spiro Rombotis
Vice Chairman/Director
Christopher Henney
Chief Financial Officer/Chief Operating Officer/Executive Vice President - Finance/Secretary/Director
Paul McBarron
Senior Vice President
Mark Kirschbaum
Director
Brian Schwartz
Director
Karin Walker
Independent Director
Samuel Barker
Independent Director
Gregory Hradsky
Independent Director
Lloyd Sems
Independent Director
Robert Spiegel
Declaration Date
Dividend Per Share
Ex-Div Date
05/26/2016
Dividend USD 0.15
07/13/2016
  • All
  • Financials
  • Insiders
More
About CYCC
Cyclacel Pharmaceuticals, Inc. operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors. Its family of anticancer drugs that act on the cell cycle include sapacitabine, seliciclib and CYC065. Its lead candidate, sapacitabine, is an orally available nucleoside analog. A number of nucleoside drugs, such as gemcitabine and cytarabine, also known as Ara-C, both generic drugs, are in use as conventional chemotherapies. Seliciclib, its lead CDK inhibitor, is an oral inhibitor of CDK2/9 enzymes that are central to the process of cell division and cell cycle control. Its second-generation CDK inhibitor, CYC065, is an inhibitor of CDKs targeting CDK2/9 enzymes with utility in both hematological malignancies and solid tumors.

Webull offers kinds of Cyclacel Pharmaceuticals Inc stock information, including NASDAQ:CYCC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CYCC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CYCC stock methods without spending real money on the virtual paper trading platform.